Key Highlights
- Shares of DOCS surged 105% to $42.39 in premarket hours following earnings despite a 4.2% EPS miss
- Management highlighted a “once-in-a-generation opportunity” in clinical artificial intelligence
- The company’s Ask AI platform topped competing U.S. models, including Anthropic’s Fable 5, in Stanford/Harvard research
- Scribe note-taking tool saw 10x year-over-year user growth in July
- Quarterly revenue reached $156.6 million, beating forecasts with 7.3% annual growth; annual guidance increased to $676 million
Shares of Doximity experienced a remarkable 105% surge in Friday’s premarket session, climbing to $42.39, as the physician-focused networking platform’s quarterly earnings presentation sparked intense investor enthusiasmādespite falling short on profitability metrics.
The financial results presented a contrasting picture. Quarterly revenue totaled $156.6 million, representing 7.3% year-over-year expansion and surpassing Wall Street’s $151.3 million projection by 3.5%. However, adjusted earnings per share of $0.29 fell beneath the consensus forecast of $0.30 by 4.2%. Adjusted EBITDA registered $74.77 million, exceeding expectations by 7.4%.
What triggered this extraordinary price movement? The answer centers on artificial intelligence.
Trading remained subdued until CEO Jeff Tangney addressed the conference call with a focus on AI capabilities. “We’re demonstrating that exceptional software margins remain achievable even while committing substantial resources to clinical AI development,” Tangney stated.
The executive characterized the moment as a “once-in-a-generation opportunity to construct the AI-powered future of healthcare.” These remarks proved sufficient to energize market participants.
Artificial Intelligence Performance Dominates Discussion
The company’s Ask AI platform demonstrated superior performance versus domestic competitors, surpassing even Anthropic’s Fable 5, according to recent academic research conducted by Stanford and Harvard teams examining medical AI applications.
Platform engagement with AI capabilities accelerated throughout the reporting period. Users of the Scribe documentation tool multiplied tenfold in July versus the prior-year comparison.
Utilization of the Search AI functionality similarly increased during the quarter, signaling expanding adoption of artificial intelligence features throughout the ecosystem.
“We serve as the digital home for physicians, and artificial intelligence represents the logical evolution of our expansion trajectory,” Tangney emphasized during the discussion.
Forward Outlook and Financial Position
Looking ahead to the upcoming quarter, Doximity projected revenue between $170 million and $171 million, with a $170.5 million midpoint. This forecast aligned closely with analyst expectations, though marginally beneath some institutional projections.
Annual revenue guidance received an upward revision to a $676 million midpoint, elevated from the previous $670 million forecast.
Annual EBITDA guidance established a $319 million midpoint, trailing analyst consensus of $329.2 million.
The quarter’s operating margin registered 21.5%, declining from 37.4% in the year-ago period. Free cash flow margin measured 25.3%, contrasting with the prior quarter’s 73.8%.
Period-end billings totaled $159.3 million, reflecting 7% annual advancement.
The organization’s market capitalization stood at $3.89 billion entering Friday’s session. This valuation changed dramatically following the 105% premarket appreciation.
Across the preceding five-year span, Doximity achieved a 21.9% compound annual revenue growth trajectory. The two-year annualized rate stands at 15.2%, indicating deceleration, while sell-side forecasts anticipate just 3.6% revenue expansion over the coming twelve months.
The company’s scribe documentation tool experienced tenfold user expansion in July on a year-over-year basis, representing the most current metric management disclosed.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
